The RSI Indicator for CERS moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 23 of the 28 cases the stock moved higher. This puts the odds of a move higher at 82%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on CERS as a result. In 84 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for CERS just turned positive on October 20, 2026. Looking at past instances where CERS's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.
Following a +7.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where CERS advanced for three days, in 170 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
CERS broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CERS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.648) is normal, around the industry mean (2.874). P/E Ratio (-77.000) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.219) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. CERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
FLGT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 01, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In 41 of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 85%.
The 10-day RSI Indicator for FLGT moved out of overbought territory on September 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 20 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FLGT as a result. In 56 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
FLGT moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FLGT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for FLGT moved above the 200-day moving average on October 02, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +2.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where FLGT advanced for three days, in 188 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
FLGT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 112 of 161 cases where FLGT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.549) is normal, around the industry mean (66.046). P/E Ratio (-7.064) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.013) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating fairly steady price growth. FLGT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FLGT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
CERS | FLGT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 36 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 93 | |
PRICE GROWTH RATING 1..100 | 49 | 55 | |
P/E GROWTH RATING 1..100 | 17 | 43 | |
SEASONALITY SCORE 1..100 | n/a | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CERS's Valuation (8) in the Medical Specialties industry is in the same range as FLGT (36) in the Medical Or Nursing Services industry. This means that CERS’s stock grew similarly to FLGT’s over the last 12 months.
CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as FLGT (100) in the Medical Or Nursing Services industry. This means that CERS’s stock grew similarly to FLGT’s over the last 12 months.
FLGT's SMR Rating (93) in the Medical Or Nursing Services industry is in the same range as CERS (94) in the Medical Specialties industry. This means that FLGT’s stock grew similarly to CERS’s over the last 12 months.
CERS's Price Growth Rating (49) in the Medical Specialties industry is in the same range as FLGT (55) in the Medical Or Nursing Services industry. This means that CERS’s stock grew similarly to FLGT’s over the last 12 months.
CERS's P/E Growth Rating (17) in the Medical Specialties industry is in the same range as FLGT (43) in the Medical Or Nursing Services industry. This means that CERS’s stock grew similarly to FLGT’s over the last 12 months.
| CERS | FLGT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 82% | 1 day ago 77% |
| Stochastic ODDS (%) | 1 day ago 85% | 1 day ago 70% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 76% |
| MACD ODDS (%) | 1 day ago 80% | 1 day ago 85% |
| TrendWeek ODDS (%) | 1 day ago 78% | 1 day ago 80% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 80% |
| Advances ODDS (%) | 2 days ago 75% | 3 days ago 69% |
| Declines ODDS (%) | 15 days ago 83% | 1 day ago 76% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 74% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 70% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CERS’s FA Score shows that 2 FA rating(s) are green while FLGT’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CERS’s TA Score shows that 4 TA indicator(s) are bullish while FLGT’s TA Score has 5 bullish TA indicator(s).
CERS (@Medical/Nursing Services) experienced а +6.70% price change this week, while FLGT (@Medical Specialties) price change was -4.19% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.
CERS is expected to report earnings on Nov 02, 2026.
FLGT is expected to report earnings on Nov 05, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-3.15% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, CERS has been loosely correlated with ICUI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To CERS | 1D Price Change % | ||
|---|---|---|---|---|
| CERS | 100% | -3.35% | ||
| ICUI - CERS | 46% Loosely correlated | +4.66% | ||
| UTMD - CERS | 45% Loosely correlated | +0.46% | ||
| RVTY - CERS | 44% Loosely correlated | +0.48% | ||
| ATRC - CERS | 43% Loosely correlated | +2.83% | ||
| DHR - CERS | 43% Loosely correlated | -1.76% | ||
More | ||||
A.I.dvisor indicates that over the last year, FLGT has been loosely correlated with MYGN. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if FLGT jumps, then MYGN could also see price increases.
| Ticker / NAME | Correlation To FLGT | 1D Price Change % | ||
|---|---|---|---|---|
| FLGT | 100% | -0.70% | ||
| MYGN - FLGT | 41% Loosely correlated | +3.41% | ||
| CERS - FLGT | 40% Loosely correlated | -3.35% | ||
| BIO - FLGT | 39% Loosely correlated | +0.83% | ||
| NVST - FLGT | 38% Loosely correlated | +3.36% | ||
| MXCT - FLGT | 38% Loosely correlated | -2.72% | ||
More | ||||